Ron Leger's questions to EOM Pharmaceutical Holdings (IMUC) leadership • Q3 2016
Question
Ron Leger from England Alternatives Investments asked for details on the increased competition for glioblastoma patients, the specifics of loosening the ICT-107 trial's screening criteria, and the level of partnership interest from large pharmaceutical companies.
Answer
CEO Andrew Gengos identified Bristol Myers Squibb's large Opdivo trials as a key source of competition, which may attract patients who prefer not to wait or undergo apheresis. He explained that screening criteria were loosened for patients post-chemo-radiation because MRIs can be difficult to interpret, and the previous standard was too stringent. Regarding partnerships, Gengos stated that while dialogues are active, large pharma companies seem to be in a 'wait-and-see' mode, wanting more definitive data before committing, despite the logical therapeutic combination with checkpoint inhibitors.